Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of QuadraMed Corp. (“QuadraMed” or the “Company”) (NasdaqGM:QDHC) arising from the Company’s announcement of its intent to be acquired by Francisco Partners in a going private transaction.

On December 8, 2009, QuadraMed announced its plan to be acquired by the private equity firm Francisco Partners. Under the terms of the merger agreement, QuadraMed shareholders will receive $8.50 in cash for every share of QuadraMed common stock they own. Just two days after the announcement of the merger, QuadraMed reported that the Department of Veterans Affairs renewed a contract with the Company worth a reported $24 million.

The investigation is focused on the potential unfairness of the consideration to be paid to QuadraMed shareholders as well as the potential unfairness of the process by which the QuadraMed Board of Directors is addressing the transaction.

If you are interested in discussing your rights as a QuadraMed shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Quadramed Corp (MM) (NASDAQ:QDHC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Quadramed Corp (MM).
Quadramed Corp (MM) (NASDAQ:QDHC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Quadramed Corp (MM).